Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP-CLAD: Pirfenidone in CLAD Post Lung-Transplant
NCT03473340Phase 2Terminated
- Sponsor
- University of Michigan
- Start
- Apr 2018
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pirfenidone in chronic lung allograft dysfunction (CLAD), sponsored by University of Michigan. Started Apr 2018; status: terminated.
02
Drugs
pirfenidone
03
Conditions
chronic lung allograft dysfunction (CLAD)
Beyond the preview
Go deeper on NCT03473340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03473340.